A Growth Investor’s Elegant Gamble on a Diminished Diagnostic Titan

According to the official scriptures of the SEC, Newtyn, with the somber air of a Victorian dilettante, augmented its position by approximately 994,332 shares-a trifle, one might say, yet enough to signify a conviction bordering on the poetic. Their stake now eclipses 2.7 million shares, valued at the modest sum of $79.5 million as of September’s close. A small fortune, certes, but in the universe of high finance, it is often the conviction, not the coin, that whispers the loudest.




